Cyclerion director granted options on 48,445 shares

Cyclerion Therapeutics director Andrew Gottesdiener received a 48,445-share stock option grant with monthly vesting through 2029, held for the benefit of Venrock Management, LLC.

Rhea-AI Filing Summary

Cyclerion Therapeutics, Inc. (CYCN) reported that director Andrew Gottesdiener received a grant of stock options covering 48,445 shares of common stock on September 9, 2026. The options have an exercise price of $26.20 per share, expire on September 9, 2036, and vest in equal monthly installments through September 9, 2029, subject to his continued service.

Under an agreement with Venrock Management, LLC, the option and underlying shares are held for the sole benefit of Venrock Management, which is entitled to the underlying shares; Gottesdiener and Venrock Management each may be deemed indirect beneficial owners, and Gottesdiener disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 48,445 shares

Grant/Award 1 txn

Insider Gottesdiener Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	48,445	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 48,445 contracts (Direct)

Footnotes (2)

1. F1. This option represents the right to purchase 48,445 shares of the Issuer's common stock and will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
2. F2. Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

Key Figures

Stock options granted: 48,445 options Exercise price: $26.20 per share Expiration date: September 9, 2036 +2 more

5 metrics

Stock options granted 48,445 options Grant to director Andrew Gottesdiener on September 9, 2026

Exercise price $26.20 per share Exercise price for the 48,445 stock options

Expiration date September 9, 2036 Option term end date for the granted stock options

Underlying common shares 48,445 shares Common stock underlying the granted stock options

Post-grant option holdings 48,445 options Total options held after the reported grant

Key Terms

Stock Option (Right to Buy), vesting, indirect beneficial owner, pecuniary interest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security titled "Stock Option (Right to Buy)" with an exercise price"

vesting financial

"will vest in equal monthly installments through September 9, 2029"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

indirect beneficial owner financial

"The Management Company may be deemed the indirect beneficial owner"

pecuniary interest financial

"disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cyclerion Therapeutics (CYCN) disclose about Andrew Gottesdiener in this Form 4?

Cyclerion Therapeutics reported that director Andrew Gottesdiener received a stock option grant for 48,445 shares of common stock on September 9, 2026, with an exercise price of $26.20 per share and expiration on September 9, 2036.

How do the 48,445 Cyclerion (CYCN) stock options granted to Andrew Gottesdiener vest?

The 48,445 stock options granted to Andrew Gottesdiener vest in equal monthly installments through September 9, 2029, and each vesting is conditioned on his continued service to the company on the applicable vesting date.

Who is the beneficial owner of the stock options reported for Cyclerion (CYCN) director Andrew Gottesdiener?

Under an agreement, the option and underlying shares are held for the sole benefit of Venrock Management, LLC, which is entitled to the underlying shares. Venrock Management may be deemed the indirect beneficial owner, and Gottesdiener disclaims beneficial ownership except for his pecuniary interest.

What is the exercise price and expiration date of the Cyclerion (CYCN) options granted to Andrew Gottesdiener?

The options have an exercise price of $26.20 per share and an expiration date of September 9, 2036, giving a 10-year term from the grant date for potential exercise, subject to applicable conditions.

Does the Cyclerion (CYCN) Form 4 indicate trades under a Rule 10b5-1 plan for Andrew Gottesdiener?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for this transaction. The reported activity is a grant of stock options, not a market purchase or sale under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:43 PM Accepted by SEC EDGAR 09/10/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gottesdiener Andrew

(Last) (First) (Middle)

C/O KORSANA BIOSCIENCES, INC.

203 CRESCENT STREET, SUITE 503

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korsana Biosciences, Inc. [ KRSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.2	09/09/2026		A		48,445		(1)	09/09/2036	Common Stock	48,445	$0.00	48,445	D(2)

Explanation of Responses:

1. This option represents the right to purchase 48,445 shares of the Issuer's common stock and will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

	/s/ Mark Vignola, as attorney-in-fact for Andrew Gottesdiener	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)